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Notch-1 Mediated Cardiac Protection following
Embryonic and Induced Pluripotent Stem Cell
Transplantation in Doxorubicin-Induced Heart Failure
Hilda Merino, Dinender K. Singla*
Biomolecular Science Center, Burnett School of Biomedical Sciences, College of Medicine, University of Central Florida, Orlando, Florida, United States of America
Abstract
Doxorubicin (DOX), an effective chemotherapeutic drug used in the treatment of various cancers, is limited in its clinical
applications due to cardiotoxicity. Recent studies suggest that transplanted adult stem cells inhibit DOX-induced
cardiotoxicity. However, the effects of transplanted embryonic stem (ES) and induced pluripotent stem (iPS) cells are
completely unknown in DOX-induced left ventricular dysfunction following myocardial infarction (MI). In brief, C57BL/6 mice
were divided into five groups: Sham, DOX-MI, DOX-MI+cell culture (CC) media, DOX-MI+ES cells, and DOX-MI+iPS cells. Mice
were injected with cumulative dose of 12 mg/kg of DOX and 2 weeks later, MI was induced by coronary artery ligation.
Following ligation, 56104 ES or iPS cells were delivered into the peri-infarct region. At day 14 post-MI, echocardiography
was performed, mice were sacrificed, and hearts were harvested for further analyses. Our data reveal apoptosis was
significantly inhibited in ES and iPS cell transplanted hearts compared with respective controls (DOX-MI+ES: 0.4860.06%
and DOX-MI+iPS: 0.3360.05% vs. DOX-MI: 1.0460.07% and DOX-MI+CC: 0.9660.21%; p,0.05). Furthermore, a significant
increase in levels of Notch-1 (p,0.05), Hes1 (p,0.05), and pAkt (p,0.05) were observed whereas a decrease in the levels of
PTEN (p,0.05), a negative regulator of Akt, was evident following stem cell transplantation. Moreover, hearts transplanted
with stem cells demonstrated decreased vascular and interstitial fibrosis (p,0.05) as well as MMP-9 expression (p,0.01)
compared with controls. Additionally, heart function was significantly improved (p,0.05) in both cell-transplanted groups.
In conclusion, our data show that transplantation of ES and iPS cells blunt DOX-induced adverse cardiac remodeling, which
is associated with improved cardiac function, and these effects are mediated by the Notch pathway.
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Introduction
Doxorubicin (DOX) is the antineoplastic drug of preference to
treat a wide variety of malignancies such as acute leukemia,
lymphoma and breast cancer, with a high survival rate among
patients [1,2]. However, the benefits of this drug become less
appealing due to the cardiotoxic side effects after treatment [3,4].
Moreover, some studies have found that patients receiving DOX
therapy had an increased risk of myocardial infarction (MI) and
that this risk persisted up to 25 years after DOX treatment [5].
DOX treatment demonstrates cardiac remodeling which results in
cardiac myocyte apoptosis and fibrosis [6–8]. Cardiac myocyte
apoptosis and heart dysfunction in DOX-induced heart failure
involves many complex mechanisms including oxidative stress and
upregulation of pro-apoptotic and downregulation of anti-
apoptotic proteins [9–12].
Adjuvant therapies have been proposed to decrease the
cardiotoxic effects of DOX. For instance, the use of antioxidants
such as probucol, taurine, and fenofibrate have been shown to
suppress DOX-induced oxidative stress and cardiac myocyte
apoptosis [13–15]. However, none of these therapies have been
shown to improve heart function at the physiological level. Since
cardiac myocytes have limited self-renewal, stem cells have
acquired significant consideration as an alternative method to
repair and regenerate cardiac cells [16]. Of note, human umbilical
cord blood derived stem cells and bone marrow-derived stem cells
have been shown to improve cardiac function and capillary density
in DOX-induced cardiomyopathy (DIC) [16–18].
Embryonic stem (ES) and induced pluripotent stem (iPS) cells
have the potential to develop into cell types from all three germ
layers compared with adult stem cells, which have a limited
plasticity, as well as attenuate apoptosis and fibrosis [19–21].
Although concerns have been raised regarding the teratoma
potential of these cells types, our published data as well as that of
others suggest teratoma formation is dose-dependent and trans-
plantation of up to 100,000 ES cells have not yielded teratomas up
to 12 weeks post-transplantation [22,23]. Notably, we reported
recently that ES cells and their condition media (CM) inhibit
apoptosis and improve cardiac function once transplanted in a
DIC model [24]. However, the mechanisms by which stem cells
attenuate cardiac remodeling and exert their benefits are not well
understood. Therefore, we hypothesize that transplanted ES and
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iPS cells inhibit cardiac remodeling (apoptosis and fibrosis),
mediated by the Notch pathway, and improve cardiac function
in a combined model of DIC and myocardial infarction. Our data
shows that transplantation of ES and iPS cells inhibits apoptosis
and fibrosis in DIC following MI. Moreover, our data demon-
strates that after transplantation of ES and iPS cells, levels of
Notch-1, Hes1 and Akt increased significantly with decreased
levels of PTEN, a negative regulator of Akt. Finally, hearts
transplanted with ES and iPS cells show a significant improvement
in cardiac function.
Materials and Methods
ES and iPS Cell Culture
CGR8 mouse ES cells were kindly provided by Michel Puceat
(Centre de Researches, INSERM, U390 France) and iPS cells
were generated from H9c2 cardiomyoblasts as previously
described [19], both of which have been used in numerous
published studies [19,20,24–26]. ES and iPS cells were maintained
in Dulbecco’s Minimum Essential Medium (DMEM, Invitrogen,
USA) containing leukemia inhibitory factor (LIF), sodium pyru-
vate, glutamine, b-mercaptoethanol, penicillin/streptomycin, non-
essential amino acids and 15% ES cell-qualified fetal bovine serum
on a 60 mm gelatin coated tissue culture plate as published by us
[20]. Moreover, activin A and bFGF were present in the iPS
growth medium but not in the ES cell medium.
DOX Treatment
All animal protocols were approved by the University of Central
Florida animal care committee as per US National Institute of
Health guidelines. C57BL/6 mice, male and female, of 8–10
weeks of age, were treated with DOX as previously reported [24].
In brief, mice were injected one time every other day (Monday,
Wednesday, and Friday) for three days with DOX to obtain a
cumulative dose of 12 mg/kg via intraperitoneal injection (IP).
Coronary Artery Ligation and Stem Cell Transplantation
Two weeks after the last dose of DOX, MI was induced by
coronary artery ligation under isoflurane inhalatory anesthesia
administered via an endo-tracheal tube as reported previously
[25,27]. In brief, a left thoracotomy was performed; the left
anterior descending (LAD) coronary artery was visualized using a
dissecting microscope and subsequently ligated using a 7.0
polypropylene suture. Subsequently, animals were divided into
five groups: Sham (No treatment), DOX-MI, DOX-MI+cell
culture (CC) media, DOX-MI+ES cells, and DOX-MI+iPS cells
with an n= 6–8 in each group. For each mouse, following ligation,
56104 ES or iPS cells were delivered into two independent sites in
the peri-infarct region, identified as the infarcted border zone
around the LAD region where the suture was placed, using a 29-
gauge floating needle. 20 ml of media was delivered in two
injections of 10 ml each at two different sites in the CC group.
Terminal Deoxynucleotidyl Transferase dUTP Nick End
Labeling (TUNEL) Assay
TUNEL staining was performed as previously reported [20]. In
brief, heart sections were deparafinized, rehydrated, and then
incubated with proteinase K (Sigma) at a dose of 25 ug/ml in
100 mM Tris-HCL for 15 minutes. Apoptotic positive nuclei were
determined by TUNEL staining according to manufacturer’s
instructions. In brief, sections were incubated with a TUNEL
reaction mixture for one hour, and then washed with 16PBS three
times. Finally, mounting media with DAPI was used to cover the
slides. Each slide was analyzed under an Olympus fluorescent
microscope. Photomicrographs were taken under 20X and the
percentage of apoptotic nuclei (red) was determined by counting
the total number of red positive cells and the total number of
nuclei (blue). Red apoptotic nuclei that merge with DAPI in blue
were considered positive. The following formula was applied to get
the percentage: (red+apoptotic nuclei/total blue nuclei)*100. One
to two sections of 6–8 animals per group were analyzed.
Caspase-3 Activity Assay
The heart was homogenized, the supernatant was collected and
protein quantification using a Bradford assay was performed.
Caspase-3 colorimetric activity assay (Bio Vision) was performed
according to the manufacturer’s instructions as previously reported
[20]. In brief, the reaction buffer, provided in the kit containing
10 mM of DTT, was added to the heart homogenates. The
specific enzyme, DEVD-pNA, was added to each sample and
incubated for 1–2 hours at 37uC. The developed colorimetric
reaction was measured at 405 nm in a 96 well microplate reader
(Biorad Model) and values plotted as arbitrary units. Data
collected from 4–8 animals per group.
Notch-1 and a-Sarcomeric Actin Double Staining
The bottom part of the heart was embedded in different ethanol
dilutions (75%, 80%, 90%, and 100%), and paraffin blocks were
formed containing the heart tissue. Five micron sections were
obtained and placed on microscope slides. A double immunoflu-
orescent staining protocol was applied as reported previously [28].
Sections from five to six different hearts in each group were
deparaffinized, rehydrated, and then blocked with a mouse
antigen blocking reagent for one hour and then incubated with
primary antibodies for mouse Notch-1 antibody (1:20 dilution,
abcam) and a monoclonal anti-a-sarcomeric actin antibody (1:30
dilution; Sigma-Aldrich). Control sections were omitted for
primary antibody. Biotinylated Anti-Mouse IgG reagent (MOM
kit, Vector Laboratories) was applied for 1 hour at room
temperature. Sections were next incubated with kit components,
fluorescein Avidin DCS (16 ul/ml) or Texas Red Avidin DCS
(15 ug/ml), respectively to develop the reaction. Washings with
PBS were performed and sections were covered with mounting
media containing 49,6-diamino-2-phenylindole (DAPI). Fluores-
cence labeled cells were identified, analyzed and representative
photomicrographs were taken under fluorescent (Olympus 1670
and Nikon TE 2000-E) and confocal (LEICA laser scanning)
microscopes. To get the percentage total Notch+ve cells where
divided to total DAPI times 100. One to two sections of 6 animals
per group were analyzed.
Sodium Dodecyl Sulfate Polyacrylamide Gel
Electrophoresis and Western Blot
Western blot analysis was performed as previously reported
[19,26]. In brief, proteins were loaded in an 8% or 10% SDS-Page
and electrophoresis was run at 150 V for 1 hour. Proteins were
transferred to a PVDF membrane (BioRad) using a Trans-Blot
Semi-dry transfer. Cell membranes were blocked with 5% skim
milk in tris-buffered saline and tween 20 for 1 hour and then
incubated with primary antibodies Notch-1 (Cell signaling),
pPTEN (Cell Signaling), pAKT (Cell Signaling), Hes1 (Abcam)
and b-actin (Cell signaling) at appropriate dilutions for 1 hour at
room temperature or overnight at 4uC. Following the incubation
of primary antibodies, secondary antibody was used and
membranes were incubated for 1 hour. Finally, membranes were
treated with an enhanced chemiluminescent substrate (ECL,
Thermo Scientific) for 1–2 min and then exposed at different
Notch-1 Protects Doxorubicin-Induced Heart Failure
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exposure times. b-actin was used as loading control. Blots from 4–
6 different experiments were scanned and band intensities from
each blot were analyzed using image J software and expressed
relative to b-actin signal.
pAkt Activity Assay
Heart homogenization and protein quantification were per-
formed as stated before. pAkt1 (PAN) activity assay (Exalpha
Biological) was performed following the directions of the
manufacturer’s instructions as reported previously [24]. In brief,
50 ul of each sample was pipetted into microtiter wells that
contain capture antibodies, provided by the manufacturer. Plates
were incubated for two hours to develop the reaction. Washings
were performed to remove any unbound material in the plates. A
biotin conjugated anti-Phospho Akt1 antibody was added to each
well and incubated for two hours. Excess antibody was washed and
a HRP-conjugated streptavidin was added to each well for 30 min
at room temperature. A colorimetric reaction was developed that
was measured at 450 nm in a microplate reader. Total protein
concentration of each sample was determined by Bradford assay.
Values obtained from the ELISA experiments were normalized to
the total protein concentration for each of the samples and were
plotted as arbitrary units. Data collected from 4–5 animals per
group.
Masson’s Trichrome Staining
Heart sections were deparaffinized and rehydrated in serial
dilutions of alcohol, then stained with Masson’s trichrome staining
following the technique reported previously [26]. In brief, sections
were incubated in Bouins Fixative for 45 min, washed and stained
with Weigert Iron Hematoxylin, Anylin Blue, and finally mounted
with Cytoseal-60 and cover slipped. Each slide was analyzed under
a brightfield microscope with the fibrotic areas stained in blue and
the healthy in red. The percentage of interstitial and vascular
fibrosis area over total interstitial and vascular area was measured
using Image J.
MMP-9 Immunoassay
MMP-9 expression was determined from heart homogenates
(n = 4–6 hearts/group) using an enzyme-linked immunoassay
(R&D Systems) as previously described and following the
manufacturer’s protocol [26]. The color reaction, proportional
to MMP-9 concentration, was quantified in a microtiter plate
reader at 450 nm. Results were corrected to protein concentra-
tion, which was determined by the Bradford assay. Data was
plotted as arbitrary units.
Echocardiographic Analysis
At day (D) 14 post-MI, two-dimensional (2D) echocardiography
was performed under 2% isoflurane via nose cone to analyze
cardiac function as previously described [24]. In brief, M-mode
images of the left ventricle were documented. Left ventricular (LV)
dimensions including LV fractional shortening (FS) and LV
ejection fraction (EF) were measured. After echocardiography
analysis was performed, animals were sacrificed using pentobar-
bital (80 mg/Kg) and cervical dislocation. The hearts were
harvested, rinsed with PBS and sectioned transversally with the
top portion kept in RNA later and the bottom portion in 10%
paraformaldehyde (PFA).
Statistical Analysis
One-way analysis of variance (ANOVA) was performed
followed by Tukey test for all samples. All values were presented
as a mean 6 SEM. p,0.05 was considered to be statistically
significant between the values.
Results
ES and iPS Cell Transplantation Decreases Apoptosis in
DIC post-MI
To determine whether ES and iPS cell transplantation has an
anti-apoptotic effect in DIC post-MI, TUNEL staining was
performed. Figure 1A–O shows representative photomicrographs
of TUNEL staining in each of the study groups at day 14 post-MI.
After quantitative analysis, we observed a significant increase in
TUNEL-positive nuclei in the DOX-MI and DOX-MI+CC
groups compared with the Sham control group (p,0.001,
Figure 1P). Notably, the percent apoptotic nuclei was significantly
reduced in DOX-MI+ES cell and DOX-MI+iPS cell transplanted
hearts compared with DOX-MI and DOX-MI+CC hearts (DOX-
MI+ES: 0.4860.06% and DOX-MI+iPS: 0.3360.05% vs. DOX-
MI: 1.0460.07% and DOX-MI+CC: 0.9660.21% TUNEL
positive nuclei/total nuclei; p,0.05; Figure 1P). Moreover, to
confirm our TUNEL results, a caspase 3 activity assay was
performed using heart homogenates from each group. Statistical
analysis of caspase 3 activity showed a significant increase in the
activity of this apoptotic marker in DOX-MI and DOX-MI+CC
groups compared with Sham (p,0.05, Figure 1Q). However, a
significant decrease in caspase 3 activity in DOX-MI+ES and
DOX-MI+iPS cell transplanted hearts was observed when
compared with the DOX-MI and DOX-MI+CC hearts (DOX-
MI+ES: 1.8860.06 A.U. and DOX-MI+iPS: 1.8760.03 A.U. vs.
DOX-MI: 2.1360.03 A.U. and DOX-MI+CC: 2.1360.04 A.U.;
p,0.05; Figure 1Q).
Transplantation of ES and iPS Cells Contributes to Cardiac
Repair in DIC post-MI Through Notch-1
Notch-1 regulates the fate of cardiac progenitor cells (CPCs) and
stimulates proliferation of cardiac myocytes [29,30]. Previous
studies have shown that after treatment with DOX, Notch-1
receptor expression levels in CPCs are low compared with its
ligands, delta-like 3 and jagged [5]. Thus, we wanted to study the
expression of Notch-1 in DIC-post MI hearts. Therefore, we
examined Notch-1+ve cells co-labeled with a-sarcomeric actin
(Figure 2A–T). Quantitative analysis of immunostaining demon-
strated Notch-1 receptor expression in DIC post-MI was
significantly decreased in DOX-MI and DOX-MI+CC groups
compared with Sham control group (p,0.05, Figure 2U).
Conversely, a significant increase of Notch1+ve cells in DOX-
MI+ES and DOX-MI+iPS cell transplanted hearts was observed
when compared with the untreated DOX-MI and DOX-MI+CC
groups (DOX-MI+ES: 1.5460.19% and DOX-MI+iPS:
1.7160.34% vs. DOX-MI: 0.7060.06% and DOX-MI-CC:
0.6960.09% Notch-1+ve cells/total nuclei; p,0.05; Figure 2U).
Moreover, western blot (WB) analysis was performed to validate
the results of our Notch-1 immunostaining. Densitometric analysis
of Notch-1 bands confirmed that expression of Notch-1 in DOX-
MI and DOX-MI+CC hearts was significantly decreased com-
pared with our control Sham group (p,0.05, Figure 2V).
Additionally, WB analysis also confirmed hearts transplanted with
ES and iPS cells contained a significantly increased percentage of
Notch-1+ve cells when compared with the untreated groups, DOX-
MI and DOX-MI+CC (DOX-MI+ES: 1.8660.22 A.U. and
DOX-MI+iPS: 1.9060.29 A.U. vs. DOX-MI: 0.8760.2 A.U. and
DOX-MI+CC: 0.8760.16 A.U.; p,0.05; Figure 2V). Statistical
analysis revealed Notch-1 expression was not significant between
DOX-MI+ES and DOX-MI+iPS groups.
Notch-1 Protects Doxorubicin-Induced Heart Failure
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Effects of ES and iPS Cell Transplantation on Hes1 in DIC
post-MI
To further characterize the effects of Notch-1 in DIC post-MI,
Hes1, a downstream effector of Notch-1, was studied. Western blot
studies were performed to study the expression of this protein in
DIC post-MI. Densitometric analysis of Hes1 WB bands
demonstrated a significant increase in expression of Hes1 in the
ES and iPS cell transplanted hearts compared with Hes1
expression in DOX-MI and DOX-MI+CC groups (DOX-MI+
ES: 1.9460.29 A.U. and DOX-MI+iPS: 1.7560.35 A.U. vs.
DOX-MI: 0.4160.11 A.U and DOX-MI+CC: 0.5660.10 A.U.;
p,0.05; Figure 3A–B). Nevertheless, Hes1 protein levels between
ES and iPS cell transplanted groups were not significant.
Akt and PTEN Expression is Regulated by ES and iPS Cells
Transplanted in DIC post-MI Hearts
Previous studies have shown that DOX treatment decreases
expression of the pro-survival protein Akt [24]. Therefore, we
studied the expression of this protein in DIC post-MI and its
modulation when ES and iPS cells were transplanted. A pAkt
ELISA was performed to analyze pAkt levels in DIC post-MI.
pAkt activity was significantly decreased in DOX-MI and DOX-
MI+CC groups compared with Sham control group (p,0.001,
Figure 4A). However, increased pAkt activity was observed in
hearts transplanted with ES and iPS cells compared with DOX-
MI and DOX-MI+CC groups (DOX-MI+ES: 42.762.45 A.U.
and DOX-MI+iPS: 43.8763.84 A.U. vs. DOX-MI: 26.7561.56
A.U and DOX-MI+CC: 22.1061.47 A.U.; p,0.05; Figure 4A).
Our ELISA data was confirmed through WB studies as shown in
Figure 4B. Furthermore, our data also suggests that the increase in
levels of activated Akt is due to the inhibition of PTEN, an Akt
inhibitor, as demonstrated by WB analysis. Densitometric analysis
of PTEN WB bands revealed a significant increase in levels of this
protein in DOX-MI and DOX-MI+CC compared with Sham
(p,0.05, Figure 4C). However, levels of PTEN were significantly
decreased in hearts transplanted with ES and iPS cells when
compared with DOX-MI and DOX-MI+CC groups (DOX-MI+
ES: 0.4860.09 A.U. and DOX-MI+iPS: 0.5060.1 A.U. vs.
DOX-MI: 1.4460.27 A.U and DOX-MI+CC: 1.5760.23 A.U.;
p,0.05; Figure 4C).
Effects of Transplanted ES and iPS Cells on Interstitial and
Vascular Fibrosis in DIC post-MI Hearts
To determine the effect of transplanted ES and iPS cells on
interstitial cardiac fibrosis and vascular fibrosis in DIC post-MI,
Masson’s trichrome staining was performed on heart sections from
Figure 1. Effects of transplanted ES and iPS cells on cardiac myocyte apoptosis using TUNEL staining. Representative
photomicrographs at 20X are shown on the left with DAPI in blue (A, D, G, J and M), TUNEL in red (B, E, H, K and N) and merged images (C,
F, I, L and O). Top right histogram (P) shows the percentage of total apoptotic nuclei at 2 weeks post-MI. Bottom right histogram (Q) shows
quantitative analysis of caspase 3 activity assay in arbitrary units. $p,0.05 vs. Sham; *p,0.05 vs. DOX-MI and DOX-MI+CC; n = 5.
doi:10.1371/journal.pone.0101024.g001
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each of the study groups. Representative photomicrographs of
Masson’s trichrome staining of interstitial fibrosis are shown in
Figure 5 (A–E). Quantitative analysis performed demonstrated
significant interstitial fibrosis is DOX-MI and DOX-MI+CC
groups compared with the control group (p,0.05, Figure 5K).
However, interstitial fibrosis was significantly decreased in DOX-
MI+ES and DOX-MI+iPS cell treated hearts compared with
DOX-MI and DOX-MI+CC groups (DOX-MI+ES:
0.4360.11 mm2 and DOX-MI+iPS: 0.3960.13 mm2 vs. DOX-
MI: 1.2660.42 mm2 and DOX-MI+CC: 1.5460.16 mm2; p,
0.05; Figure 5K). Next, quantitative analysis of vascular fibrosis in
heart sections (Figure 5, F–J) revealed that DOX-MI+ES and
DOX-MI+iPS cell transplanted hearts contained significantly less
vascular fibrosis than DOX-MI and DOX-MI+CC groups (p,
0.05, Figure 5L).
To elucidate mechanisms by which ES and iPS cells propagate
fibrosis inhibition in DIC post-MI myocardium, MMP-9, a
mediator of extracellular matrix (ECM) degradation and subse-
quent fibrosis, was quantified. MMP-9 expression was significantly
enhanced in the DOX-MI and DOX-MI+CC groups compared
to the Sham control group (p,0.01; Figure 5M). Notably, MMP-9
concentration was significantly reduced following ES and iPS cell
transplantation (DOX-MI+ES: 1.4860.25 A.U. and DOX-MI+
iPS: 1.5560.26 A.U. vs. DOX-MI: 3.9760.56 A.U and DOX-
MI+CC: 3.9760.44 A.U.; p,0.01; Figure 5M).
ES and iPS Cell Delivery in DIC post-MI Model Improves
Cardiac Function
Two weeks following MI surgery, cardiac function was analyzed
using 2D echocardiography. Our data demonstrates a significant
impairment of left ventricle (LV) function expressed as fractional
shortening (FS) and ejection fraction (EF) in DOX-MI and DOX-
MI+CC groups compared to the Sham control group (p,0.001;
Figure 6A–B). Cumulative quantitative data revealed a significant
improvement in fractional shortening at 2 weeks post MI in DOX-
MI+ES and DOX-MI+iPS cell treated hearts compared with
DOX-MI and DOX-MI+CC groups (p,0.05; Figure 6A). Finally,
DOX-MI+ES and DOX-MI+iPS transplanted hearts had a
significant improvement in ejection fraction compared with
DOX-MI and DOX-MI+CC groups (DOX-MI+ES:
76.4361.88% and DOX-MI+iPS: 77.7861.39% vs. DOX-MI:
67.4263.30% and DOX-MI+CC: 63.5161.63%; p,0.05;
Figure 6B).
Discussion
Doxorubicin is one of the most conventionally used anthracy-
cline drug currently on the market for the treatment of various
neoplastic diseases. Although its efficacy is widely accepted in the
clinical arena in the aforementioned capacity, DOX has been
shown to have dose-dependent deleterious effects on intrinsic
cardiac architecture and function; these cardiotoxic consequences
to include promotion of cardiac myocyte apoptosis, hypertrophy,
Figure 2. Effects of transplanted ES and iPS cells on Notch-1 expression. Representative photomicrographs are shown on the left with
Notch-1 in red (A, B, C, D and E), a-sarcomeric actin in green (F, G, H, I and J), DAPI in blue (K, L, M, N and O) and merged images (P, Q, R, S and
T). The white arrows (T) indicate the region that was magnified and shown within the boxed region. Scale bar = 20 mm. Top right histogram (U)
shows percentage of Notch-1+ve cells at 2 weeks post-MI. Bottom right panel and histogram (V) show representative Notch-1 blot and associate b-
actin with densitometric analysis. $p,0.05 vs. Sham; *p,0.05 vs. DOX-MI and DOX-MI+CC; n= 6.
doi:10.1371/journal.pone.0101024.g002
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enhanced susceptibility to MI, dilated cardiomyopathy, and
impaired ejection fraction [5–8]. Limited studies have provided
insight into the salutary impact propagated by transplanted stem
cells in the DOX injured myocardium but, to date, no studies have
been undertaken to elicit the effects of cellular therapy in the
DOX-induced post-MI heart [16,18,24,31]. In the present study,
we have generated a DIC post infarction mouse model and
evaluated the response of the injured myocardium to the
transplanted ES and iPS cells as well as identified signaling
molecules, including Notch-1, Hes1, PTEN, and Akt, which play a
pivotal role in the cytoprotective mechanisms conferred by our
transplanted stem cells. To the best of our knowledge, this is the
first investigation into the cytoprotective impact of iPS and ES cells
in the DIC post-MI injured myocardium.
Previously suggested, apoptosis plays a monumental role in
cardiac myocyte cell death in DIC and post-MI hearts contrib-
uting to hypertrophy, fibrosis, diminished cardiac function, and
heart failure [20,32,33]. Consistent with these earlier studies, our
disease mouse model (DOX-MI and DOX-MI+CC) contained
significantly elevated apoptotic nuclei relative to the sham
operated mice as evidenced by TUNEL staining and a caspase-3
activity assay. Our data further suggests that following stem cell
transplantation in the DIC post-MI heart, apoptosis is significantly
attenuated. Our findings are in accordance with previous
independent investigations in which they demonstrated trans-
planted stem cells alleviate DIC and post-MI cardiac myocyte
apoptosis [16,20,24].
Functional characteristics of the Notch pathway in the heart
include differentiation, cardiac myocyte expansion, valve forma-
tion, and cardioprotection during assault [34–36]. Inversely,
ventricular septal anomalies, valve aberrations, and exacerbated
hypertrophy and apoptosis have been reported as a result of Notch
dysregulation [36–38]. Recently, De Angelis et al reported Notch-
1 expression was significantly downregulated in CPCs following
DOX treatment [1]. To this end, we evaluated changes in Notch-1
expression consequent to DIC post-MI induction and stem cell
transplantation. In the control treatment groups (DOX-MI and
DOX-MI+CC), a significant reduction in Notch-1 expression was
observed compared to the sham controls. Conversely, a previous
study reported increased levels of Notch-1 in the border zone of
the infarct region post permanent coronary ligation [29]. We
hypothesize variances in the experimental design including
different animal models and our use of DOX account for the
discrepancies reported in the expression levels of Notch-1 post-MI
[29]. To the best of our knowledge, we are the first to show that
expression of Notch-1 is significantly diminished in DIC post-MI
hearts and suggest its dysregulation plays a role in post DOX-MI
cardioprotection loss. Notably, we report a significant elevation in
Notch-1 expression in both stem cell transplanted groups
compared to the DIC post-MI control hearts. We suggest the
enhanced Notch-1 expression observed within the ES and iPS cell
transplanted DIC post-MI myocardium is consequent to paracrine
mechanisms mediated by the stem cells.
Figure 3. Effects of transplantation of ES and iPS cells in Hes1
in DIC post-MI. (A) Upper panel displays representative photomicro-
graphs of WB bands of Hes1 and b-actin. (B) Bottom histogram shows
densitometric analysis of WB bands with a significant increase in levels
of Hes1 in groups treated with ES and iPS cells. *p,0.05 vs. DOX-MI and
DOX-MI+CC; n = 5.
doi:10.1371/journal.pone.0101024.g003
Figure 4. Effects of transplanted ES and iPS cells on Akt and PTEN expression in DIC post MI. Left histogram (A), reveals a significant
increase in pAkt activity in hearts transplanted with ES and iPS cells. $p,0.001 vs. Sham; *p,0.05 vs. DOX-MI and DOX-MI+CC; n = 4–5. (B) Top middle
panel displays representative photomicrographs of WB bands for pAkt and b-actin and bottom middle histogram shows densitometric analysis of WB
bands with a significant increase in levels of pAkt levels in ES and iPS cell treated hearts. $p,0.05 vs. Sham; *p,0.05 vs. DOX-MI and DOX-MI+CC;
n = 4–5. Upper right panel (C) shows representative WB bands of PTEN and b-actin and bottom right histogram shows densitometry analysis of WB
bands with a significant decrease in levels of PTEN in hearts transplanted with ES and iPS cells. $p,0.05 vs. Sham; *p,0.05 vs. DOX-MI and DOX-MI+
CC; n = 4–6.
doi:10.1371/journal.pone.0101024.g004
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To further elucidate the involvement of Notch-1 in cardiac
repair and protection in the DIC post-MI heart, Hes1, a Notch-1
downstream target gene, was also investigated. Activation of Hes1
is an indirect response to activation of Notch by Delta/Jagged
ligands and leads to downregulation of various targets [29,39].
Our data implicates a dramatic increase in Hes1 expression
following ES and iPS cell transplantation into the DIC post-MI
heart compared to the DOX-MI and DOX-MI+CC groups. The
pathway by which ES and iPS cells, transplanted in the DIC post-
MI heart, promote activation of Notch-1 and its downstream
effectors is largely unknown and will require further investigations.
Recent studies have suggested an interaction between the Notch
pathway and the pro-survival PI3K/Akt pathway [39]. Specifi-
cally, Hes1 was shown to negatively regulate PTEN, an inhibitor
of PI3K/Akt signaling, in thymocytes and T-cell lymphoblastic
leukemia (T-ALL) cells [39,40]. Our data corroborates these
previous findings and suggests an inverse relationship between
activation of pAkt and inhibition of PTEN expression in our study
groups. In the DOX-MI and DOX-MI+CC groups, p-Akt
expression was significantly downregulated and PTEN significant-
ly upregulated comparable to the sham control group. Conversely,
when DIC post-MI hearts were transplanted with ES or iPS cells,
levels of Akt were dramatically elevated and levels of PTEN were
drastically diminished relative to controls (DOX-MI and DOX-
MI+CC). It is feasible to suggest that upregulation of Notch-1 and
subsequent activation of Hes1 lead to abrogation of PTEN
transcription, thus preventing the inhibition of Akt activation.
Fibrosis plays a major role in adverse cardiac remodeling in
DIC and post-MI myocardium. As expected, DIC post-MI hearts
without stem cell transplantation presented elevated quantities of
interstitial and vascular fibrosis. On the contrary, hearts
transplanted with ES or iPS cells showed significant reduction in
the amount of both interstitial and vascular fibrosis. Supporting
evidence of our findings include previously published articles
demonstrating decreased fibrosis post stem cell transplantation in
DIC and infarcted myocardium and Notch regulation of
fibrogenesis [20,24,36]. Furthermore, MMP-9, a well-recognized
mediator of adverse ventricular fibrosis and subsequent remodel-
ing, was evaluated to establish a relationship between ES and iPS
cells and blunted fibrosis in the DIC post-MI myocardium.
Consistent with previous studies, transplantation of ES and iPS
cells significantly abolished MMP-9 activation suggesting mecha-
nisms of fibrosis inhibition within the current study may be similar
to those reported in other MI and DOX studies [41–43].
However, future studies are needed to identify augmented fibrotic
pathways within the ES and iPS cell transplanted DIC post-MI
heart.
Figure 5. Effects of transplanted ES and iPS cells on cardiac fibrosis. Representative photomicrographs of interstitial fibrosis (A–E), with
fibrotic tissue in blue and healthy cardiac tissue in pink and vascular fibrosis (F–J). Bottom left histogram (K) shows a significant decrease in interstitial
fibrosis (mm2) at 2 weeks post-MI in ES and iPS cell treated groups. $p,0.05 vs. Sham; *p,0.05 vs. DOX-MI and DOX-MI+CC; n = 5–7. Bottom middle
histogram (L) shows quantitative analysis of vascular fibrosis over total vascular area with a significant decrease in vascular fibrosis percentage in
DOX-MI+ES and DOX-MI+iPS groups when compared with DOX-MI and DOX-MI+CC. $p,0.05 vs. Sham; *p,0.05 vs. DOX-MI and DOX-MI+CC; n = 4–6.
Bottom right histogram (M) shows quantitative analysis of MMP-9 expression for all treatment groups. $p,0.01 vs. Sham; *p,0.01 vs. DOX-MI and
DOX-MI+CC; n = 4–6.
doi:10.1371/journal.pone.0101024.g005
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Finally, we needed to determine the effects of transplanted ES
and iPS cells on overall cardiac function in the DIC post-MI
myocardium. DIC and post-MI myocardium contribute to
anomalous left ventricular stiffness and systolic dysfunction
[4,20,24]. Within the current study, we demonstrate poor cardiac
function in DOX-MI and DOX-MI+CC mice. However, DIC
post-MI mice receiving stem cell transplantation exhibited
significantly improved fractional shortening and ejection fraction
compared to their non-stem-cell-transplanted DIC post-MI
counterparts. We acknowledge that mechanisms leading to
improved cardiac function are complex and multifaceted. We do
however suggest that the reduction in apoptosis and fibrosis is
directly related to the improvement in ventricular function
observed within the present study. Conceivably, it is possible to
note that cardiac function modulation may be attributable to the
cardioprotective effects of the Notch pathway activation (Figure 6,
C).
Stem cell transplantation, most notably ES cells, coincides with
concerns of teratoma formation. In the current study, we report no
evidence of teratoma formation in hearts transplanted with iPS or
ES cells (data not shown). Our findings are in agreement with
various published investigations indicating no teratoma formation
following transplantation of less than 300,000 stem cells [20,26].
Furthermore, our DIC post-MI model exhibited no indication of
immune rejection following stem cell transplantation as reported
previously by us and others [24,44].
In conclusion, the major findings of the present study include
the following for the first time: In the DIC post-MI heart,
following ES and iPS cell transplantation, (1) apoptosis was
significantly inhibited, (2) Notch-1 and Hes-1 expression were
significantly increased, (3) fibrosis and MMP-9 expression were
significantly diminished, (4) Akt activation was significantly
enhanced and PTEN levels were abolished, and (5) cardiac
dysfunction was mitigated. We would like to point out that our
findings suggest transplanted iPS and ES cells have similar
cytoprotective potential within the DIC post-MI myocardium.
Furthermore, our findings are novel and, for the first time, provide
evidence indicating the Notch pathway plays a role in DIC post-
MI cardioprotection. However, future studies are warranted, using
specific inhibitors of the Notch and Akt pathways, to understand
the exact mechanisms by which ES and iPS cells protect the DIC
post-MI myocardium from apoptosis and fibrosis.
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Figure 6. Effects of transplanted ES and iPS cells on cardiac function. Left top (A) histogram show that average left ventricular fractional
shortening percentage (FS) significantly improved 2 weeks post-MI in the ES and iPS cell treated groups when compared with DOX-MI and DOX-MI+
CC. $p,0.001 vs. Sham; *p,0.05 vs. DOX-MI and DOX-MI+CC. Left bottom (B) histogram show that average left ventricular ejection fraction
percentage (EF) significantly improved 2 weeks post-MI in the ES and iPS cell treated groups compared with DOX-MI and DOX-MI+CC groups. $p,
0.001 vs. Sham; *p,0.05 vs. DOX-MI and DOX-MI+CC; n = 4–8 animals. Right diagram (C) is a representation of the predicted pathway by which stem
cells contribute to cardioprotection and improved left ventricular function in the DIC post-MI heart.
doi:10.1371/journal.pone.0101024.g006
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